Track Cell Source's receivables ($50K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Cell Source (CLCS) currently reports a receivables of $50K as of December 2024. In the prior-year period, the figure was $0. Use the charts on this page to explore Cell Source's receivables history and peer comparisons.
Cell Source's receivables changed from $0 to $50K (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Cell Source reported $50K in receivables as of December 2024. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current receivables of $50K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cell Source, and consider following CLCS for alerts when major investors trade the stock.
Cell Source is classified in the Healthcare sector. On receivables, it currently shows $50K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CLCS with unrelated industries.